Cellectis(ENXT) ALCLS

Cellectis S.A. is a clinical-stage biotechnology company based in Paris, France, specializing in immuno-oncology. Founded in 1999, the company focuses on developing gene-edited T-cell therapies to target and eliminate cancer cells.

Products and Services

• Allogeneic CAR T-cell product candidates for various cancers
• Strategic partnerships with leading biotech firms and research institutions
• Innovative gene-editing technologies for therapeutic applications

Growth Outlook

• Strong pipeline with multiple CAR T-cell candidates in clinical trials
• Recent strategic collaborations enhance research capabilities and market reach
• Potential for significant market share in the growing immuno-oncology sector

Financial Highlights

• Recent quarterly revenue of €5.68 million, showing growth potential
• Trailing twelve months (TTM) revenue of €35.17 million, indicating upward trend
• Current ratio of 1.52, reflecting solid liquidity position

Cellectis S.A. operates in the dynamic biotechnology sector, focusing on innovative solutions for cancer treatment. The company's commitment to developing allogeneic CAR T-cell therapies positions it well within the rapidly expanding immuno-oncology market. Recent collaborations with prominent partners further strengthen its research capabilities and market presence. Financially, Cellectis has demonstrated growth potential, with a recent quarterly revenue of €5.68 million and a TTM revenue of €35.17 million. The company's current ratio of 1.52 suggests a healthy liquidity position, which is crucial for sustaining operations and funding ongoing research initiatives. Overall, Cellectis S.A. presents an intriguing opportunity for investors interested in the biotechnology field, particularly in the area of cancer therapies.